$CELG Company News Liquid growth stocks tell

New Post Public Reply Private Reply Replies (0) Message Board

Dec 12, 2014 at 11:41 AM

$CELG Company News

Liquid growth stocks tell interesting tale 3:11 p.m. Dec. 9, 2014 - The Trading Deck
H&R Block shares fall on quarterly miss 6:42 p.m. Dec. 8, 2014 - Wallace Witkowski
The S&P 500 recorded its biggest drop in nearly 7 weeks 4:33 p.m. Dec. 8, 2014 - Anora Mahmudova
Celgene shares climb 1.9% 9:31 a.m. Dec. 8, 2014 - Sue Chang
Is the next Cisco out there? 3:24 p.m. Nov. 25, 2014 - The Trading Deck
5 charts show how stock repurchases boost prices 6:00 a.m. Nov. 18, 2014 - Ophir Gottlieb
The double-edged sword of growth-stock speculation 2:30 p.m. Nov. 14, 2014 - The Trading Deck
Two biotech leaders to watch 1:13 p.m. Oct. 28, 2014 - The Trading Deck
Celgene profit up 37%, raises outlook 7:42 a.m. Oct. 23, 2014 - MarketWatch.com
Be ready to play another market surge 11:25 a.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 5:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 2:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 10:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
Celgene shares up on news of positive late-stage drug trial 6:42 a.m. Sept. 4, 2014 - Ciara Linnane
How retail sector sets up stocks at the end of summer 2:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 10:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 3:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 10:44 a.m. July 24, 2014 - Russ Britt
Biogen results crush consensus 3:55 p.m. July 23, 2014 - The Trading Deck
Nasdaq needs to turn up the volume 10:59 a.m. July 17, 2014 - The Trading Deck

Celgene Takes Over #14 Spot From Edison International 12:52 p.m. Dec. 11, 2014 - TheStreet.com
Celgene's Abraxane Succeeds In Early Breast Cancer 10:27 a.m. Dec. 11, 2014 - Investors Business Daily
Tell Me How You Really Feel: A Look At The Market Through Analyst Consensus Recommendations 8:02 a.m. Dec. 11, 2014 - Seeking Alpha
Cramer's Mad Money - The Good Isis (12/10/14) 4:43 a.m. Dec. 11, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: The Good News-Bad News of Lower Oil Prices 8:41 p.m. Dec. 10, 2014 - TheStreet.com
How To Invest: Don't Mix CAN SLIM With Other Systems 5:09 p.m. Dec. 10, 2014 - Investors Business Daily
Adaptive Asset Allocation: Experimentation With A Large Stock Portfolio 1:53 p.m. Dec. 10, 2014 - Seeking Alpha
Allergan Leads The 20 Best Value Bond Trades With A Maturity Of 1 Year Or More 12:17 p.m. Dec. 10, 2014 - Seeking Alpha
Stock Market News for December 10, 2014 - Market News 10:10 a.m. Dec. 10, 2014 - Zacks.com
Are Investors Signaling Optimism in Biotechs Through Short Interest? 9:24 a.m. Dec. 10, 2014 - 247WallSt.com
Celgene Up on Positive Revlimid Data Presented at ASH - Analyst Blog 4:40 p.m. Dec. 9, 2014 - Zacks.com
Bluebird Bio Stock Spikes On New Blood Treatment 1:10 p.m. Dec. 9, 2014 - Investors Business Daily
Multiple myeloma patients have a rough time with Celgene's pomalidomide 8:28 a.m. Dec. 9, 2014 - Seeking Alpha
Top Analyst Upgrades and Downgrades: Cisco, DreamWorks, Lululemon, Nabors, Schlumberger, Verizon and More 7:51 a.m. Dec. 9, 2014 - 247WallSt.com
Amgen Unveils Positive Results from Blood Cancer Studies - Analyst Blog 7:05 p.m. Dec. 8, 2014 - Zacks.com
Agios (AGIO) Reports Encouraging Data on Leukemia Drug - Analyst Blog 4:35 p.m. Dec. 8, 2014 - Zacks.com
Stocks Are Dragged Lower as Oil Prices Plunge to 5-Year Low 4:24 p.m. Dec. 8, 2014 - TheStreet.com
Stocks Recover From Session Lows Though Oil Prices Continue to Hurt 3:30 p.m. Dec. 8, 2014 - TheStreet.com
Celgene, Acceleron Pharma Report Prelim. Data from Ongoing Phase 2 Trials in Patients with Lower Risk MDS:: Luspatercept, Sotatercept Increased Hemoglobin Levels 1:04 p.m. Dec. 8, 2014 - benzinga.com
Celgene Offers Results from Phase III Study of REVLIMID, Showed Improved Transfusion Independence 12:51 p.m. Dec. 8, 2014 - benzinga.com

Data Presented on REVLIMID® (lenalidomide) Compared with Investigators’ Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma 8:34 p.m. Dec. 8, 2014 - BusinessWire - BZX
Additional Analyses of High-Risk Patients from Phase III Study (AML-001) OF Vidaza® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition 2:00 p.m. Dec. 8, 2014 - BusinessWire - BZX
Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH 1:49 p.m. Dec. 8, 2014 - BusinessWire - BZX
Age, Renal Impairment and Depth of Response Analyses of the FirstTM (MM-020/IFM 07-01)Study of Continuous REVLIMID® (lenalidomide) Plus Low-Dose dexamethasone in Newly-Diagnosed Multiple Myeloma Presented at ASH 9:58 p.m. Dec. 7, 2014 - BusinessWire - BZX
Critical Alerts For Noodles & Company, Goldcorp, YY, Celgene and LinkedIn Released By InvestorsObserver 9:31 a.m. Dec. 2, 2014 - PR Newswire - PRF
Celgene Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Corporation 4:30 p.m. Dec. 1, 2014 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis 6:00 a.m. Nov. 21, 2014 - BusinessWire - BZX
Chef Michael Ferraro, the Pancreatic Cancer Action Network and Meals to Heal Team up with Celgene to Address Nutritional Needs and Challenges Faced by Pancreatic Cancer Patients and Caregivers 8:00 a.m. Nov. 20, 2014 - BusinessWire - BZX
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV 4:29 p.m. Nov. 19, 2014 - Marketwired
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV 3:35 p.m. Nov. 19, 2014 - Marketwired
Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis 7:30 a.m. Nov. 18, 2014 - BusinessWire - BZX
Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases 9:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alibaba, Bloomin' Brands, VoxelJet, 51job and Celgene Released By InvestorsObserver 9:31 a.m. Nov. 5, 2014 - PR Newswire - PRF
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 31, 2014 - BusinessWire - BZX
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014 7:35 a.m. Oct. 20, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shell Seals ARC Acquisition, $16.5B Bet on Future

Shell’s Strategic Play: Snagging ARC When it comes to Shell, they don't dawdle with peanuts. Snagging ARC Resources Ltd., a Canadian energy firm rooted squarely in British Columbia and Alberta, speaks volumes about their appetite for growth. They’re shelling out approximately US$16.5 billion to pull this deal off the ground. This isn't just some casual sector play; it...

HIMS Faces Class Action: Investors Eye Leadership

Another Day, Another Lawsuit: Hims & Hers in Hot Water Here's the latest conundrum in the corporate world, folks. Hims & Hers Health, Inc. (NYSE: HIMS) is caught up in a class action lawsuit that could shake up the telehealth scene. Investors who found themselves knee-deep in losses during the class period from August 2025 to July 2026 might want to pay attention. The...

VT Markets Appoints Maxwell for Global Expansion

Maxwell Joins VT Markets Amid Strategic Shift Forget the usual humdrum of C-suite comings and goings; this one's packed with punch. VT Markets is setting the stage for a serious leap forward by naming Ross Maxwell their new Chief Strategy Officer. This isn't just another desk job—it's a pivotal role meant to integrate cutting-edge technology with the ever-evolving...

RealityMine Appoints CPO Amidst Strong Growth Momentum

Pushing the Boundaries of Behavioral Data When a company like RealityMine posts a whopping 75% year-over-year revenue bump, you know they're not here to mess around. Enter Soumya Bijjal, a seasoned pro stepping in as their inaugural Chief Product Officer. This isn't just about adding to the C-suite boys' club; it's about locking in on a goldmine of behavioral data that's...

Capricor Faces Lawsuit: Investors Should Take Note

Capricor Therapeutics: A Rough Road Ahead If you've got skin in the game with Capricor Therapeutics, these latest developments might have you feeling a bit queasy. Forget the greasy diner fare today; this situation calls for some serious contemplation and maybe a bit of antacid. Over at NASDAQ:CAPR, the air is hot with allegations, stock price nosedives, and looming legal...

Joseph Spine Opens New Regenerative Therapy Center

Regenerative Medicine: A New Frontier in Spine Care When spine care gets a facelift, you take notice. Joseph Spine Institute, a heavyweight in the spine care game, just threw hat into the regenerative ring. We're talking about using a patient's own cells to mend what's broken—that's advanced. They're launching a Regenerative Therapy Center in Tampa, ready to offer these...

Check Point Shareholders Back 2026 AGM Proposals

Shareholder Endorsement Solidifies Check Point's Strategy Today, Check Point Software Technologies had a bit of a celebratory mood. Their stakeholders, it seems, aren't just riding the wave; they're all in. You could almost hear the cheers from Redwood City when those shareholder voting results flashed across the board. Some 81.2 million shares—encompassing about 79.52%...

TCOM Secures $600M Deal to Boost NATO's Defense

TCOM's Pivotal $600 Million Defense Contract How often do you hear about a deal north of $600 million that practically revamps a company's strategic future? That's precisely what's hitting the books at TCOM right now. They've scored a heavy-hitting Foreign Military Sales (FMS) contract to fortify NATO's eastern front with Poland. I'll tell you this—it’s one of the...

ITP Media's Bold Move: Ready for Asian Market Surge

Pushing Boundaries: ITP Media Group Eyes Asia ITP Media Group isn't here to tiptoe around the media market; they're diving headfirst with the recent takeover of Heart Media Group. A bold move, some might say, in this volatile world of media mergers and acquisitions. But let's break down what this really means. A Strategic Bet on Luxury To start, ITP Media is beefing up...

Ecobat's Strategic Shift: Exiting Lithium for Lead

You ever get that sense of déjà vu when another company decides to jump ship from a supposedly hot market? Well, that's where Ecobat's at, folks. This global player in battery recycling just waved goodbye to its lithium recycling biz, closing the deal on its Arizona operations. Previously, they ditched similar holdings in the UK and Germany. Now, they're all-in on their...